Professional Documents
Culture Documents
Investor Presentation
Q4 & FY22
Safe Harbour
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have
been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be
made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no
representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness
of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any
liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are
individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of
the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the
Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and
advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The
Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this
Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements
and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party
statements and projections.
All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy,
timeliness or completeness.
2
Q4 & FY22 Financial Performance
Q4 & FY22 – Performance Snapshot
Operational & Financial Highlights – Q4 FY22 Operational & Financial Highlights – FY22
2.45 Mn 9.32 Mn
Tests Tests
INR 1,162.0 Mn INR 4,623.7 Mn
Revenue Revenue
0.96 Mn 3.62 Mn
Footfalls Footfalls
4
Key Operational Highlights (1/2)
Annual Quarterly
Tests Performed (# in Million)
3% Y-o-Y
9.32 2.45
2.38
7.91 2.32
6.99 7.09
Footfalls (# in Million)
8% Y-o-Y
3.62 0.96
0.89 0.85
2.79 2.63
2.38
5
Key Operational Highlights (2/2)
Annual Quarterly
Revenue per Test (INR)
1,265 1,303
1,212
1,431
1,228 1,214 1,276
6
Revenue – COVID, COVID Allied and Non-COVID
(INR Mn)
Annual Quarterly
Non-COVID Revenue
-2% Y-o-Y
3,930
3,388 1,004 1,022 983
3,124
2,926
694 179
643
21
108 170 117
20 86
10 158
535 524
96 76
0 0
FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22
COVID COVID Allied *COVID revenue includes RT-PCR, Antibody tests and COVID Allied tests like IL-6 and D- Dimer
7
Key Financial Highlights
(INR Mn)
Annual Quarterly
Revenue from Operations
4% Y-o-Y
4,624 1,120 1,162
1,108
3,767
3,388
2,926
1,097 314
845 253 237
625
459
Cost of materials consumed 178.8 162.6 10% 163.0 10% 715.0 570.9 25%
Employee benefits expense 192.0 151.7 27% 182.2 5% 706.6 574.3 23%
Other expenses 312.7 261.5 20% 284.3 10% 1,165.2 962.4 21%
Depreciation and amortization expense 152.8 125.5 22% 130.1 17% 526.9 504.5 4%
Profit before Tax 314.3 426.1 -26% 338.5 -7% 1,473.8 1,121.2 31%
Tax expenses 75.5 109.2 -31% 83.9 -10% 367.2 270.0 36%
Profit before Minority Interest 238.8 316.8 -25% 254.6 -6% 1,106.7 851.3 30%
Minority Interest 1.7 2.7 -36% 1.7 -2% 9.9 6.5 52%
Profit after Tax (PAT) 237.1 314.2 -25% 252.9 -6% 1,096.8 844.8 30%
*Not annualized
9
Company Overview
Vijaya at a Glance
Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 95 state-of-the-art centres spread across 16 cities
40+ 95
Mission Years of Experience Centres Quality
Awarded Brand of the year in diagnostic One of the earliest private diagnostic
Recognized as one of the Best Imaging services by The CEO Magazine and service providers to be approved for
Vijaya Diagnostic Centre centres in Hyderabad by The Week Telangana Healthcare Leadership award COVID RT-PCR testing by ICMR*
incorporated in Hyderabad
Investment by Karakoram
Awarded Best Diagnostic
First independent diagnostic centre Limited and Kedaara Capital Successfully listed on Indian Stock
Centre – India by Times
in South India to offer PET CT from Alternative Investment Fund – Exchanges (NSE & BSE)
Healthcare Achievers Group
Wipro GE Healthcare Pvt. Ltd. Kedaara Capital AIF1
First independent diagnostic centre in
Telangana to get Revolution ACT 50 slice CT
from Wipro GE Healthcare Pvt. Ltd
*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange
12
At the Forefront of Introducing New Technologies
Integrated modular
DNA fragmentation COVID testing by RT-PCR Philips DS Achieva with
2019 Index test in semen
2020 solution for Immunoassay 2020 2021
in Telangana & AP Ambient Experience
& Chemistry assays
13
Our Pillars of Strength
14
Indian Diagnostics Market expected to Grow at a Healthy Trajectory
(INR Bn)
Radiology Pathology
980 980
Rest of India
Flagship
Centre
#1 #1
Reference Lab
Customers
Hubs
#23
Samples
#11
Customer (Walk-in)
Home Collection
B2B Hospitals & Labs
Sample Flow
Patient Flow
Diagnostic
Centres
/ Spokes
#71
Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT)
Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT)
Diagnostic Centre / spokes = Lab Samples Collection + Basic Radiology
Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.
17
…offering One-Stop Solutions for Pathology & Radiology
18
High brand recall driving customer stickiness
(INR)
Sticky individual customer
1,431
1,228 1,214 1,276
20 200+
Fully Integrated Radiology
Advance Laboratory
MRI Machines Radiologists, Lab Doctors & Information Systems (RIS) and
Information Management
Physicians Picture Archive and
System (LIMS)
Communication Systems (PACS)
5 11
Front end IT infrastructure enabling…
NABH Accreditations NABL Accreditations
• At the forefront of introducing new tests by adopting the latest medical Provide Uniform Experience to
technologies customers from booking
appointments to accessing
• Among the first diagnostic service provider in South India to offer PET-CT scan reports online
Monitor Technical
in 2008
Operations
20
Experienced Board of Directors
Dr. S Surendranath Reddy - Executive Chairman Dr. D Nageshwar Reddy - Non-executive, Independent Director
Founder of Vijaya with 40+ years of experience in building Vijaya as South
India’s largest integrated diagnostic chain Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad
Holds Bachelor’s degree in Medicine and Provisional degree of Doctor of Awarded Padma Shri and Padma Bhushan by Government of India
Medicine in Radiology D.M in Gastroenterology from PGIMER Chandigarh
21
Strong Management Team
Dr. S. Surendranath Reddy Mr. Sunil Chandra Kondapally Ms. Suprita Reddy Mr. Narasimha Raju K.A Ms. Anusha Kanumuru
Executive Chairman Executive Director Chief Executive Officer Chief Financial Officer Company Secretary &
Compliance Officer
40+ years of experience in With Vijaya since incorporation With Vijaya since 2003 and Associated with Vijaya from 12 + years of experience in
building Vijaya as South India’s and experienced in operations, heads overall strategy, clinical June 2017 to Nov 2020 and handling works relating to public
largest integrated diagnostic quality accreditation, finance, excellence, operations and rejoined in March 2021 issue(s), private placement(s),
chain marketing and network expansion of the company 14+ years of experience in merger(s), foreign investment,
Holds Bachelor’s degree in expansion departments Awarded Women Leadership audit, financial reporting, listing formalities with the Stock
Medicine and Provisional 17+ Years of experience in Award in Healthcare by ABP in regulatory compliance and Exchanges, Company Law, FEMA
degree of Doctor of Medicine healthcare industry & founded 2019 accounting advisory and Stock Exchange Compliances
in Radiology Trikona Pharmaceuticals Pvt. Holds bachelors degree in Previously worked with SR including regulatory approvals
He is a life member of the Ltd. (2016) and QPS Bioserve commerce from Osmania Baltliboi & Co., NSL Renewable Associate member of ICSI and
Indian Radiological and India Pvt. Ltd. (2004) University Power Pvt. Ltd. etc holds Bachelor's degree in
Imaging Association. Holds bachelor’s degree in Holds bachelor’s degree of Commerce and Corporate Affairs
electrical engineering from commerce from Osmania Previously worked with
Florida State University University and member of the Aurobindo Realty, IVRCL Ltd etc
Institute of Chartered
Accountants of India
22
Awards & Accolades
One of the Best Healthcare Indo Global Award for Company of the Year - Leading Diagnostic Chain of the India’s Greatest Leaders 2020-21
Brands 2021 Healthcare Excellence Healthcare Year Ms. Suprita Reddy - CEO
India’s Greatest Brands 2020-21 Leading Diagnostics with Most Trusted and Best Quality Healthcare Entrepreneur of the Fastest Growing Brands
Pride of Nation Excellence in Quality & Safety Diagnostic services in India Year – Dr. Surendra Reddy (Pride of the Nation)
Best Diagnostic Centre of the Leading Chain of Diagnostics & Best Diagnostic Service Provider Most Trusted Diagnostic Centre Telangana Healthcare
Year Imaging of the Year of the Year Leadership Awards
2019 2019
2019 2019 Presented by 2018
Presented by
Presented by Presented by Indo-Arab Presented by
Indian Medical
Times Healthcare Six Sigma Leaders Telangana
Association,
Achievers Healthcare Summit & Government
Telangana state and
Messe India Awards
23
Shareholding Pattern
Others
Shareholding Pattern as of 31st March 2022
FII’s
4.0% Category % Holding
24
Strategy Going Forward
Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh
26
Expand in Adjacent Geographies & East India
Network (FY22)
Expand in concentric circles given our Hence, Kolkata to be our focus area for
hub and spoke model medium to long term growth
61-68
Rest of the Wellness & Rest of the
Wellness &
market Preventive market
Preventive
90% 9% - 10% 89%
11%
FY20 FY23
Increasing chronic and lifestyle diseases Increase diagnostic services by offering additional preventive and wellness services through adoption of
new cutting-edge diagnostic testing technology
Corporate tie-ups Providing home collection services and point-of-contact testing to complement walk-in
Increasing disposable income Expand specialty tests, disease specific profiles and provide customized packages
Increasing service offerings Grow our corporate customer base by catering to their needs
Expansion of chronic disease management and wellness programs
95 3.62 9.32
80 7.91
73 2.79 6.99 7.09
61 2.63
2.38
FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22
Test per Footfall (Nos) Revenue per Test (INR) Revenue per Footfall (INR)
Impact of COVID-19
531
496 1,431
2.93 2.83
2.69 419 428 1,276
2.57 1,228 1,214
FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22
30
Consistent Financial Performance
(INR Mn)
CAGR:16%
4,624 CAGR:24% 1,097
2,037
CAGR:34%
3,767
3,388 1,660 845
2,926
1,326 625
1,081
459
FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22
22.4% 23.7%
44.1% 44.1%
18.5%
15.7%
39.1%
37.0%
1,729
1,215
43% 23%
38% 23% 23%
33% 22%
30%
ROCE (Pre-cash): PBIT ex Other income / (Total Assets – Cash – Current Liabilities) CFO = Cash flow from Operations
32
Annexure
Consolidated Profit & Loss Account
(INR Mn)
34
Consolidated Balance Sheet
(INR Mn)
Assets Mar-22 Mar-21 Mar-20 Mar-19 EQUITY AND LIABILITIES Mar-22 Mar-21 Mar-20 Mar-19
*Current investments + investments with maturity more than 12 months (part of other non-current financial assets) 36
THANK YOU
Vijaya Diagnostic Centre Limited (VDCL) Citigate Dewe Rogerson (CDR India)
www.vijayadiagnostic.com anoop@cdr-india.com
devrishi@cdr-india.com
#6-3-883/F, Ground Floor, FPAI Building, Punjagutta, Officers Colony, Near Topaz Building, Hyderabad-500082, Telangana, India.